Document is current
Any future updates will be listed below
-
Authors
Li, Zhongqi https://orcid.org/0000-0003-2554-9334
Chen, Xinyi
Vong, Joaquim S. L. https://orcid.org/0000-0002-5859-2008
Zhao, Lei
Huang, Junzhe
Yan, Leo Y. C.
Ip, Bonaventure
Wing, Yun Kwok https://orcid.org/0000-0002-5745-5474
Lai, Hei-Ming
Mok, Vincent C. T. https://orcid.org/0000-0002-8102-8835
- License Information
-
More Information
Article History
Received: 9 February 2021
Accepted: 11 May 2021
First Online: 2 June 2021
Competing interests
: C.U.H.K. filed a patent application based partly on the discovery reported in the study. Z.L., X.C., J.S.L.V., L.Z., J.H., L.Y.C.Y., H.M.L., V.C.T.M., and H.K. are inventors on the patent. Exenatide used in the study was provided by AstraZeneca Hong Kong Limited. AstraZeneca Hong Kong Limited had otherwise no role in the funding, design, execution or data interpretation of the study. All other authors declare no competing interests.
